Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Harry Schneider

Podiatrist, Foot & Ankle Surgery Cambridge, MA Doctor of Podiatric Medicine

NPI 1245342914 CMS profile 282848

1493 Cambridge St, Dept. Of Surgery, Cambridge, MA 02139

Open in the dashboard

General payments

$174,122

326 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Harry Schneider of Cambridge, MA is reported in the CMS Open Payments database as having received $174,122 across 326 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,971 11
2024 General $46,972 55
2023 General $27,237 52
2022 General $31,357 72
2021 General $38,031 51
2020 General $9,419 21
2019 General $16,135 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Harry Schneider
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Harry Schneider were reported at $4,971. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Harry Schneider Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $16,135 $389 $118–$1,406 $163
2020 $9,419 $191 $62–$691 $114
2021 $38,031 $329 $104–$1,341 $132
2022 $31,357 $419 $125–$1,611 $149
2023 $27,237 $377 $128–$1,164 $160
2024 $46,972 $394 $134–$1,168 $164
2025 $4,971 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $169,478 277 payments
  2. Kairos Surgical Inc $1,242 3 payments
  3. Medline Industries, Inc. $1,101 2 payments
  4. Integra LifeSciences Corporation $732 10 payments
  5. Osiris Therapeutics Inc. $470 5 payments
  6. BonaliveInc $167 1 payment
  7. Stryker Corporation $163 4 payments
  8. LifeNet Health $140 1 payment
  9. Orthofix Medical, Inc. $122 3 payments
  10. Wright Medical Technology, Inc. $81 4 payments
  11. Other $427 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $130,313 64 payments
  2. Travel and Lodging $22,895 140 payments
  3. Consulting Fee $12,834 6 payments
  4. Food and Beverage $6,546 113 payments
  5. Education $1,200 1 payment
  6. Long term medical supply or device loan $333 2 payments
Products named General payments · program years 2019–2025
  1. STRAVIX Extremities & Limb Restoration $110,380 162 payments
  2. GRAFIX Other Advanced Wound Management $102,877 142 payments
  3. GRAFIX PL $75,940 131 payments
  4. OASIS $65,680 74 payments
  5. GRAFIX XC Other Advanced Wound Management $57,397 73 payments
  6. STRAVIX PL $37,857 92 payments
  7. Stravix Other Advanced Wound Management $18,826 49 payments
  8. GRAFIX Other Advanced Wound Management $14,464 31 payments
  9. STRAVIX Extremities & Limb Restoration $8,408 11 payments
  10. GRAFIX XC Other Advanced Wound Management $7,840 19 payments
  11. Other $71,889 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

198

Median for Podiatry: 160

Drug cost

$2,840

Median for Podiatry: $2,368

Branded share of claims

9.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 91 $1,033
Ammonium Lactate Generic 24 $650
Diclofenac Sodium Generic 24 $529
Terbinafine Hcl Generic 23 $404
Pregabalin Generic 17 $132
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 19 $93

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$36,633

Medicare's payments for the services billed

Medicare patients

209

Average age 72

Services billed

644

118 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 49%
Arthritis 48%
Chronic kidney disease 33%
Depression 30%
Ischemic heart disease 28%
Heart failure 22%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

326 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record